Cervical Stenosis
On this page
Direct answer
Narrowing or obliteration of the cervical canal — usually acquired, a late consequence of cone biopsy or LLETZ, destructive treatments, radiotherapy, postmenopausal atrophy or chronic infection — defines cervical stenosis. Its consequences follow the blockage: menstrual blood or secretions accumulate behind a closed canal producing haematometra with cyclical pain and absent or scanty menses, pyometra in the infected postmenopausal uterus, and — the quiet clinical problem — inability to sample the endometrium or pass instruments. Management is dilatation, ideally ultrasound-guided in difficult cases, with topical oestrogen pre-treatment when atrophy is the cause, and hysterectomy reserved for refractory symptomatic disease.
What you must remember
- Causes: post-cone-biopsy and LLETZ scarring (a recognised late effect of treating CIN), cautery and radiation for cervical cancer, postmenopausal oestrogen deficiency, severe cervicitis, and rarely congenital atresia.
- Haematometra picture: a premenopausal woman with increasing cyclical pelvic pain and progressively scanty or absent menses after cervical treatment; the uterus is tender and globular, and ultrasound shows an echogenic fluid-filled cavity.
- Pyometra: in the postmenopausal woman, a stenosed cervix can seal infection and pus behind it — a presentation that also demands exclusion of cervical and endometrial malignancy as the underlying cause.
- The sampling problem: stenosis blocks endometrial pipelle and hysteroscopy — the woman with postmenopausal bleeding whose endometrium "cannot be obtained" is a classic exam scenario; persistent failure needs hysteroscopic assessment under anaesthesia rather than false reassurance.
- Dilatation technique: sequential dilators, often ultrasound-guided to prevent false passage and perforation of the soft postmenopausal uterus; cervical ripening adjuncts and regional or general analgesia improve success.
- Postmenopausal pre-treatment: topical vaginal oestrogen for several weeks before attempted dilatation or sampling softens atrophic tissue and raises success rates.
- Fertility relevance: stenosis after LLETZ is one recognised contributor to subfertility and dysmenorrhoea in young women treated for CIN — a trade-off of treatment worth counselling.
- Definitive option: hysterectomy for recurrent collections, refractory pain or when malignancy must be excluded definitively; recurrent stenosis after dilatation is common, so expectations are set accordingly.
Two women, one blocked canal
A 31-year-old had a cone biopsy for CIN 3 two years ago; since then her periods have shrunk to spotting and she presents with 10 days of escalating lower abdominal pain. Ultrasound shows a 6 cm fluid collection in the uterine cavity. The canal admits nothing beyond a probe. Under ultrasound guidance, sequential dilators reopen the canal, dark old blood drains, and the pain resolves on the table — haematometra from scarring at the transformation zone, with counselling that recurrence is likely and that future fertility advice follows. Now the second woman: 71 years old, bleeding episodes, and her GP's pipelle has failed twice. She arrives with topical oestrogen used for six weeks; under anaesthesia with ultrasound cover, the canal dilates, hysteroscopy shows an atrophic cavity with one polyp, and directed biopsy settles the diagnosis. Had she been febrile instead, the same canal would have held a pyometra — draining first, antibiotics second, and cancer exclusion third. One anatomy, three emergencies hiding behind it.
How the exam frames it
Examiners anchor on the causation chain: LLETZ and cone today, stenosis and haematometra in a later viva year — the candidate who connects treatment of CIN to its mechanical legacy earns the thread. The recurring stem is the postmenopausal bleeder with failed sampling; the expected answer names the risk (endometrial carcinoma cannot be dismissed on a failed biopsy), the escalation (hysteroscopy with directed biopsy under anaesthesia, ultrasound guidance) and the pre-treatment trick (topical oestrogen for atrophy). Another favourite contrasts Asherman syndrome — intrauterine adhesions with a patent cervix — against stenosis, where the problem sits at the canal; both cause cycle disruption but the operations that cause them differ. Students should also carry the perforation caution: the postmenopausal, previously irradiated uterus is thin and unyielding, so blind dilatation here produces false passages — hence ultrasound guidance as the quotable safety step. Pyometra completing the triad (blood, pus, silence) is the closing mark.
Frequently asked questions
What are the commonest causes of cervical stenosis?
Cervical scarring after cone biopsy, LLETZ or radiotherapy, postmenopausal oestrogen deficiency, and severe or chronic cervicitis.
How does haematometra present?
Cyclical pelvic pain with scanty or absent menses and a tender, globular uterus — ultrasound shows fluid distending the endometrial cavity.
Why is failed endometrial sampling in stenosis dangerous?
Postmenopausal bleeding cannot be dismissed without tissue; persistent failure requires hysteroscopy and directed biopsy under anaesthesia to exclude carcinoma.
How is dilatation made safer in these women?
Ultrasound guidance during sequential dilatation, pre-treatment with topical oestrogen for atrophy, and analgesia — all reduce false passage and perforation risk.
When is hysterectomy considered?
For recurrent haematometra or pyometra, refractory pain after repeat dilatation, or when malignancy cannot be excluded by sampling.